The US regulator is currently assessing an additional application for VTAMA cream to treat atopic dermatitis. Organon recently acquired Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology offerings. This acquisition includes VTAMA cream, an FDA-approved treatment for plaque psoriasis. The cream is nonbiologic and non-steroidal, and is used by adults with mild to severe psoriasis. The application under review could allow the cream to also treat atopic dermatitis in people aged two and older, with a decision expected by late 2024.
As part of the acquisition deal from September 2024, Dermavant could receive up to $1.2 billion from Organon, including an initial $175 million payment and a $75 million payment if the cream gets regulatory approval. Organon will make further payments based on sales milestones and will pay royalties on net sales to Dermavant’s shareholders.
Organon’s CEO, Kevin Ali, expressed enthusiasm about adding innovative treatments like VTAMA to their portfolio, which could help millions with skin conditions like psoriasis and potentially atopic dermatitis. The rights to VTAMA are held by Dermavant everywhere except China, with Japan’s rights already licensed out. Organon will also take on Dermavant’s liabilities, valued at approximately $286 million. Legal and financial advice for the acquisition was provided by several firms.